Journal of Jilin University(Medicine Edition) ›› 2022, Vol. 48 ›› Issue (2): 505-512.doi: 10.13481/j.1671-587X.20220230
• Clinical medicine • Previous Articles Next Articles
Rongrong XU1,Yuan LU1,Jianming ZHOU2,Dandan PENG3,Xiaoli ZHU1,Shuhua HAN1(
)
Received:2021-07-09
Online:2022-03-28
Published:2022-05-10
Contact:
Shuhua HAN
E-mail:hanshuhua0922@126.com
CLC Number:
Rongrong XU,Yuan LU,Jianming ZHOU,Dandan PENG,Xiaoli ZHU,Shuhua HAN. Paraganglioma with pulmonary metastasis:[J].Journal of Jilin University(Medicine Edition), 2022, 48(2): 505-512.
| 1 | LAM A K Y. Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours[J]. Endocr Pathol, 2017, 28(3): 213-227. |
| 2 | MOON J K, MATTEI P. Pheochromocytoma and paraganglioma[J]. Semin Pediatr Surg, 2020, 29(3): 150926. |
| 3 | NEUMANN H P H, YOUNG W F, ENG C. Pheochromocytoma and paraganglioma[J]. N Engl J Med, 2019, 381(6): 552-565. |
| 4 | PACAK K, TAÏEB D. Pheochromocytoma (PHEO) and paraganglioma (PGL)[J]. Cancers, 2019, 11(9): 1391. |
| 5 | LENDERS J W, DUH Q Y, EISENHOFER G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2014, 99(6): 1915-1942. |
| 6 | LENDERS J W M, EISENHOFER G. Update on modern management of pheochromocytoma and paraganglioma[J]. Endocrinol Metab Seoul Korea, 2017, 32(2): 152-161. |
| 7 | TURCHINI J, CHEUNG V K Y, TISCHLER A S, et al. Pathology and genetics of phaeochromocytoma and paraganglioma[J]. Histopathology,2018,72(1): 97-105. |
| 8 | DAHIA P L. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity[J]. Nat Rev Cancer, 2014, 14(2): 108-119. |
| 9 | KAVINGA GUNAWARDANE P T, GROSSMAN A. The clinical genetics of phaeochromocytoma and paraganglioma[J].Arch Endocrinol Metab,2017,61(5): 490-500. |
| 10 | ROSALES-CASTILLO A, BUSTOS-MERLO A, PADILLA L G. Hereditary multiple paraganglioma[J]. Med Clin, 2021, 157(9): 455-456. |
| 11 | JOCHMANOVA I, ABCEDE A M T, GUERRERO R J S, et al. Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents[J]. J Cancer Res Clin Oncol, 2020, 146(4): 1051-1063. |
| 12 | KING K S, PRODANOV T, KANTOROVICH V, et al. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations[J]. J Clin Oncol, 2011, 29(31): 4137-4142. |
| 13 | NEUMANN H P H, YOUNG W F, ENG C. Pheochromocytoma and paraganglioma[J]. N Engl J Med, 2019, 381(6): 552-565. |
| 14 | FANG F, DING L, HE Q,et al.Preoperative management of pheochromocytoma and paraganglioma[J]. Front Endocrinol (Lausanne), 2020, 11: 586795. |
| 15 | JOCHMANOVA I, WOLF K I, KING K S, et al. SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations[J]. J Cancer Res Clin Oncol, 2017, 143(8): 1421-1435. |
| 16 | TUFTON N, SAHDEV A, AKKER S A. Radiological surveillance screening in asymptomatic succinate dehydrogenase mutation carriers[J]. J Endocr Soc, 2017, 1(7): 897-907. |
| 17 | JAIN A, BARACCO R, KAPUR G. Pheochromocytoma and paraganglioma-an update on diagnosis, evaluation, and management[J]. Pediatr Nephrol, 2020, 35(4): 581-594. |
| 18 | TANABE A, NARUSE M, NOMURA K, et al. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma[J]. Horm Cancer, 2013, 4(2): 103-110. |
| 19 | JAWED I, VELARDE M, DÄRR R, et al. Continued tumor reduction of metastatic pheochromocytoma/paraganglioma harboring succinate dehydrogenase subunit B mutations with cyclical chemotherapy[J]. Cell Mol Neurobiol, 2018, 38(5): 1099-1106. |
| 20 | NOMURA K, KIMURA H, SHIMIZU S, et al. Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy[J].J Clin Endocrinol Metab,2009,94(8):2850-2856. |
| 21 | FUJIWARA Y, OHMOTO A, FUKUDA N, et al. Clinical features and outcomes of metastatic pheochromocytoma treated by cytotoxic chemotherapy[J]. Endocr J, 2021, 68(6): 671-681. |
| 22 | VOGEL J, ATANACIO A S, PRODANOV T, et al. External beam radiation therapy in treatment of malignant pheochromocytoma and paraganglioma[J]. Front Oncol, 2014, 4: 166. |
| 23 | JASIM S, JIMENEZ C. Metastatic pheochromocytoma and paraganglioma: Management of endocrine manifestations, surgery and ablative procedures, and systemic therapies[J]. Best Pract Res Clin Endocrinol Metab, 2020, 34(2): 101354. |
| 24 | JOCHMANOVA I, PACAK K. Genomic landscape of pheochromocytoma and paraganglioma[J]. Trends Cancer, 2018, 4(1): 6-9. |
| 25 | GONCALVES J, LUSSEY-LEPOUTRE C, FAVIER J, et al. Emerging molecular markers of metastatic pheochromocytomas and paragangliomas[J]. Ann Endocinol(Paris), 2019, 80(3): 159-162. |
| 26 | SARKADI B, MESZAROS K, KRENCZ I, et al. Glutaminases as a novel target for SDHB-associated pheochromocytomas/paragangliomas[J]. Cancers, 2020, 12(3): 599. |
| 27 | RAI S K, BRIL F, HATCH H M, et al. Targeting pheochromocytoma/paraganglioma with polyamine inhibitors[J]. Metabolism, 2020, 110: 154297. |
| 28 | CASSOL C A, WINER D, LIU W, et al. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas[J]. Mod Pathol, 2014, 27(8): 1050-1062. |
| [1] | Xin LIU,Yuyang ZHANG,Deling ZENG,Xiaoqin LIU,Lu ZHANG,Meiying LI,Hong CHEN,Bangrong CAO,Shiqi MA. Levels of KLRG1 +NK cells in peripheral blood of NSCLC patients and their clinical significances [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 746-754. |
| [2] | Qiaotong REN,Weihua WU,Xingxiang WANG,Shichao WANG,Yipeng CHENG,Chun LI. Effect of interleukin-17 recepter B gene silencing on proliferation, invasion and apoptosis of lung adenocarcinoma A549 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 738-745. |
| [3] | Yang LI,Shiyang LI,Hongmei ZHANG,Qianqian LIU,Yubing CHEN. Effect of NGFR gene expression differences on promotion of apoptosis of squamous cell carcinoma and adenocarcinoma cells by PD-1 inhibitor-activated T lymphocytes [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 680-693. |
| [4] | Lei TANG,Peinan LIN,Ling ZHANG,Haiyan XU,Fengchun ZHANG. Chemotherapy efficacy and plasma drug concentration changes in patient with limited-stage small cell lung cancer complicated with uremia: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1687-1694. |
| [5] | Xiaoshuang HE,Lina XU,Mei CUI,Yu ZHAO,Bei WANG,Zheng HUANG,Yuchao WANG,Wenyan XIN,Chao WU. Effects of lncRNA DUXAP8 in lung cancer A549 cells-derived exosomes on lung cancer cell growth and its mechnism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(4): 958-967. |
| [6] | Xingxiang WANG,Ying ZHAO,Qiaotong REN,Hefei WANG,Gang PU,Chun LI. Promotive effect of M2 macrophages on epithelial-mesenchymal transition and cisplatin resistance in non-small cell lung cancer A549 cells by regulating NF-κB signaling pathway [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 642-652. |
| [7] | Yihui WANG,Qing ZHANG,Yingnan LI,Liping YE. Effect of KIAA1522 on proliferation, migration, and invasion of lung cancer cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 727-739. |
| [8] | Congcong BAI,Xianlei ZHOU,Zhi ZHANG,Shuang GAO,Xuemei ZHANG. Expression of CSPG4P12 gene in small cell lung cancer tissue and its effect on behaviors of cell biology [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 392-402. |
| [9] | Bo LIU,Chao SUN,Xu WANG,Kewei MA. Bioinformatics analysis on differentially expressed genes in multiple primary lung cancers based on GEO database [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 437-446. |
| [10] | Xiaoming WANG,Xueye WANG. Invasive adenocarcinoma of lung complicated with metastatic NUT midline carcinoma of mediastinal lymph node: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2024, 50(3): 825-830. |
| [11] | Aihua REN,Yanbo DONG,Runzhi MIAO,Yujiao LYU,Yanfeng LIU. Effect of ganoderic acid A on glycolysis and its key rate-limiting enzymes of non-small cell lung cancer PC9 cells [J]. Journal of Jilin University(Medicine Edition), 2024, 50(3): 682-688. |
| [12] | Yuan WANG,Zhijuan WANG,Mingshu ZHANG,Yihui WANG,Qing ZHANG,Liping YE. Effects of monocyte chemoattractant protein-1 on invasion and migration of lung cancer A549 and their mechanisms [J]. Journal of Jilin University(Medicine Edition), 2024, 50(3): 666-675. |
| [13] | Zongjun CHEN,Yahong CHEN,Liyun HUANG,Ziying LIANG. Effects of genomic instability and MYC gene mutation of non-small cell lung cancer A549 cells on resistance of gemcitabine [J]. Journal of Jilin University(Medicine Edition), 2024, 50(2): 355-363. |
| [14] | Aihua REN,Xinda JU,Aofei LIU,Yongchao LIU,Yanfeng LIU. Effect of ganoderic acid A on proliferation and apoptosis of human non-small cell lung cancer PC-9 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(6): 1466-1472. |
| [15] | Xiaodong GAI,Ying ZHAO,Hefei WANG,Chengyuan HE,Xingxiang WANG,Chun LI. Regulatory effect of FOXP3 on chemosensitivity of non small-cell lung cancer A549 cells to doxorubicin and its mechnism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(5): 1161-1167. |